Cytokinetics to present at 25th Annual Needham Virtual Healthcare Conference on April 13, 2026

Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, announced its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The event will be webcast live and archived for 90 days on the company's website. Cytokinetics is known for its cardiac myosin inhibitor MYQORZO® (aficamten), approved for obstructive hypertrophic cardiomyopathy, and is developing other cardiac muscle therapies. This presentation offers investors insight into the company's pipeline and future prospects.